BioSpace News Archive

ImmunoGen, Inc. today announced that multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer to be held on March 18-21, 2022 in Phoenix, Arizona.

NeonMind Biosciences Inc. today provided a summary of business highlights on the Company’s activities and progress across its Pharmaceutical and Medical Services Divisions.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference, which is scheduled to take place virtually from March 15 – March 17, 2022.

Umbra Applied Technologies Group, Inc’s, announced that its subsidiary, Ossifix Orthopedics has entered into full scale production of its Javelin fixation pin.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, provided a business update for the fourth quarter ended December 31, 2021.

Cipher Pharmaceuticals Inc. announced that it has entered into a second amended and restated distribution and supply agreement with Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, India.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced its financial results for the fourth quarter and full year of 2021, ended December 31, 2021.

Omega Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2021.

Covalon Technologies Ltd., an advanced medical technologies company, announced that Dr. Samantha Nutt has been elected a Director subject to TSX approval and Mr. Martin Goldfarb has retired as a Director of the Covalon Board.

IMV Inc. today announced that it will hold a conference call and webcast on Thursday, March 17, 2022, at 8:00 a.m. ET to discuss the company’s 2021 fourth quarter and fiscal year-end financial and operational results.